LncRNA DLEU2 promotes tumour growth by sponging miR‐337‐3p in human osteosarcoma

Liu, Wei; Liu, Pengcheng; Ma, Ke; Wang, Yuanyi; Chi, Qing‐bao; Yan, Mingxia

doi:10.1002/cbf.3509

Cited by 12 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its high expression was significantly associated with the pathological grading and TNM stage of GC patients. This result is consistent with previous research reports that also used RT-qPCR to detect the expression pattern of DLEU2 in other types of tumor tissues and cell lines.DLEU2 also is found to be highly expressed in other types of tumors, such as non-small cell lung cancer [23], glioma [24], esophageal cancer [25,26], osteosarcoma [27], and hepatocellular carcinoma [28,29] tissues and cell lines. Furthermore, we used siRNA and pcDNA3.1 plasmid transfection to knock down and exogenously express DLEU2 in GC cells respectively, and found that knockdown of DLEU2 inhibited the proliferation of AGS and MKN-45 cells, and induced cell apoptosis.…”

Section: Discussionmentioning

confidence: 99%

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

Han

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Gastric cancer (GC) remains an important cancer worldwide. Further understanding of the molecular mechanisms of gastric carcinogenesis will enhance the diagnosis and treatment of GC. Methods The expression of DLEU2 and ETS2 was analyzed in several GC cell lines using GEPIA online analyze, qRT-PCR and immunohistochemistry. The biological behavior of GC cells was detected by CCK8, clone formation, transwell, wound healing, western blot, and flow cytometry assay. More in-depth mechanisms were studied. Results DLEU2 was significantly up-regulated in GC tissues and cell lines. The expression of DLEU2 was significantly associated with pathological grading and TNM stage of GC patients. Furthermore, knockdown of DLEU2 inhibited the proliferation, migration, and invasion of AGS and MKN-45 cells, while overexpression of DLEU2 promoted the proliferation, migration, and invasion of HGC-27 cells. MiR-30a-5p could directly bind to the 3’ UTR region of ETS2. Moreover, DLEU2 bound to miR-30a-5p through the same binding site, which facilitated the expression of ETS2. Knockdown of DLEU2 reduced the protein level of intracellular ETS2 and inhibited AKT phosphorylation, while overexpression of DLEU2 induced the expression of ETS2 and the phosphorylation of AKT. ETS2 was highly expressed in GC tissues. The expression of ETS2 was significantly associated with age, pathological grading, and TNM stage. ETS2 overexpression promoted cell proliferation and migration of AGS and MKN-45 cells. Furthermore, ETS2 overexpression rescued cell proliferation and migration inhibition induced by DLEU2 down-regulation and miR-30a-5p up-regulation in AGS and MKN-45 cells. Conclusions DLEU2 is a potential molecular target for GC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

Han

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…44 The function of LncRNA DLEU2 in suppressing tumorigenesis and progression was reported recently, including esophageal cancer, 45 hepatocellular carcinoma, 46 pancreatic cancer, 47 laryngeal squamous cell carcinoma 48 and osteosarcoma. 49 On the contrary, some reports suggested that a pro-oncogenic role of DLEU2 in cancers, such as clear cell renal cell carcinoma. 50 These studies suggested that DLEU2 might show different functions in different cancer types due to the tissue specificity.…”

mentioning

confidence: 99%

<p>Knockdown of LncRNA DLEU2 Inhibits Cervical Cancer Progression via Targeting miR-128-3p</p>

Wang

Hang

et al. 2020

OTT

View full text Add to dashboard Cite

Objective: Cervical cancer is one of the most common female malignancies worldwide and represents a major global health challenge. The fast growth of tumor and high rates of metastasis still lead to a poor prognosis of cervical cancer patients. It is urgent to clarify the mechanism and identify predictive biomarkers for the treatment of cervical cancer. Long non-coding RNAs (LncRNAs) have been identified in cervical cancer and are related to malignant phenotypes of cervical cancer cells. However, the roles and mechanism of LncRNA deleted in lymphocytic leukemia (DLEU2) in the tumorigenesis and progression of cervical cancer remain unknown. Materials and Methods: qPCR was performed to analyze the expression of DLEU2, Cyclin D1, CDK4, Bax, Bcl2 and mi-128-3p. Western blot was performed to detect the cell cycle hallmarks expression. CCK8 was used to examine cell proliferation. Cellular apoptosis was analyzed by Hoechst 33,258 staining and AV/PI staining with flow cytometry. Cell cycle was analyzed by flow cytometry. The xenograft model in nude mice was used to elucidate the function of DLEU2 in vivo. Bioinformatics analysis and luciferase reporter assay were proceeded to clarify whether miR-128-3p directly binds with lncRNA DLEU2. Pull-down assay and RNA-binding protein immunoprecipitation assay were used for exploring the relationship between DLEU2 and miR-128-3p. Results: We demonstrated that DLEU2 was upregulated in cervical cancer tumor tissues. Downregulation of DLEU2 inhibited cell proliferation, induced apoptosis and cell cycle arrest at G2/M phase of cervical cancer cells in vitro, and suppressed tumor growth in vivo. Further, LncRNA DLEU2 is one of the targets of miR-128-3p. miR-128-3p inhibitor abrogated the cell proliferation suppressed by knockdown of DLEU2, apoptosis induced by knockdown of DLEU2 and reversed the expression of cell cycle hallmarks regulated by knockdown of DLEU2. Conclusion: Taken together, these results suggested knockdown of DLEU2 inhibited cervical cancer progression via targeting miR-128-3p.

show abstract

“…Herein, we screened 6 osteosarcoma-related genes by lncRNA microarray, MALAT1, HCG9, FAM99A, FAM87B, DLEU2, and C8orf49. MALAT1 and DLEU2 have been shown to promote osteosarcoma progression in previous studies [ 31 , 32 ]. FAM99A, FAM87B, and C8orf49 have not been reported in osteosarcoma studies and are rarely reported in other cancers.…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p

Wang

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Long noncoding RNAs (lncRNAs) have critical regulatory functions in biological and pathological activities during osteosarcoma progression. It is important to elucidate the expression pattern and reveal the underlying mechanisms of the newly identified lncRNAs. Methods. Herein, we screened the differentially expressed lncRNAs in osteosarcoma tumors and cell lines using lncRNA microarray. The candidate lncRNA was further verified by qRT-PCR, and the association of gene expression with clinicopathological features was evaluated by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The targeting miRNA was identified using starBase analysis, and the competing endogenous RNA (ceRNA) network was established by STRING. Overexpression and silence of RNA were detected by qRT-PCR. Osteosarcoma cell proliferation was measured with CCK-8 assay, and the migration and invasion were evaluated with Transwell assay. Colony formation assay was observed. Flow cytometry evaluated the cell cycle. Western blot was performed to detect the mitotic markers and apoptosis-related proteins. A nude mouse tumor formation experiment was used to evaluate osteosarcoma progression in vivo. Cooverexpressing miR-34b-3p with RAD51 reversed the miR-34b-3p-induced changes in proliferation, the cell cycle, the expression of H2A.X, and that of apoptosis-related proteins. Results. HCG9 was identified as osteosarcoma-associated lncRNA. Osteosarcoma tissues and cell lines expressed higher levels of HCG9 as compared to normal tissues and osteoblasts, and high expression of HCG9 was further proved to be related to metastasis and the grade of osteosarcoma in clinical cases. Knockdown of HCG9 inhibited the proliferation, migration, and invasion of osteosarcoma cells. miR-34b-3p was identified as the target of HCG9, and RAD51 acted as a potential target of miR-34b-3p. Cooverexpressing miR-34b-3p with HCG9 partially suppressed the HCG9-stimulated proliferation, migration, and invasion of osteosarcoma cells in vitro and delayed the tumor progression in vivo. Conclusion. We discovered that lncRNA HCG9 promoted the proliferation of osteosarcoma cells via suppressing miR-34b-3p. Our study provides novel biomarkers and potential therapeutic targets for osteosarcoma treatment.

show abstract

LncRNA DLEU2 promotes tumour growth by sponging miR‐337‐3p in human osteosarcoma

Cited by 12 publications

References 21 publications

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p

<p>Knockdown of LncRNA DLEU2 Inhibits Cervical Cancer Progression via Targeting miR-128-3p</p>

Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p

Contact Info

Product

Resources

About